Cover news reporter Ma Mengfei
After the frost fell, chengdu rained more and more, and the whole city entered a faster rhythm.
For Jiang Hao, "fast pace" is his daily state. On the afternoon of the 27th, after a seminar, Jiang Hao took time to meet with reporters, and after a brief exchange, he rushed to another date. Today, he is going to Jinggangshan to attend a professional forum meeting for several days.
Jiang Hao
Jiang Hao has long been accustomed to running non-stop, for him, this is both work and dream chasing. Jiang Hao is a "post-80s" returnee Dr. and the founder of Sichuan Proheles Biotechnology Co., Ltd., a biomedical company dedicated to improving the early screening and early treatment of digestive tract tumors, although it has not been established for a long time, it has enjoyed a high reputation in the industry.
And all this stems from a original intention and ideal of Jiang Hao: in his lifetime, seeing what he does can have some impact on this society.
"Post-80s" doctors returned to China to start a business
"I am a Native of Shandong, I have been in Chengdu for almost two years, I like the city very much, and I have plans to live in Chengdu for a long time." Jiang Hao smiled and said that he called himself a "Rong Drift". Jiang Hao is 39 years old this year, but his resume is very rich. In addition to being the founder of Prochars, he is also a professor and doctoral supervisor at West China Hospital of Sichuan University.
Jiang Hao's career began in 2006. In 2006, Jiang Hao graduated from Xiamen University with a bachelor's degree in biotechnology. After graduating from university, Jiang Hao came to the Shanghai Institute of Biochemical Cell of the Chinese Academy of Sciences for graduate school. He graduated with a Ph.D. in November 2012 and went to Johns Hopkins University in the United States to study in a joint training manner during his Ph.D. period.
After graduating with a doctorate, Jiang Hao continued his postdoctoral studies at Johns Hopkins University in the United States, and in August 2016, he worked as a professor in the School of Life Sciences of Sun Yat-sen University through the "100 Talents Program" of Sun Yat-sen University.
In 2019, Jiang Hao officially became acquainted with Sichuan. "What I do is clinically translated, and in this regard, West China Hospital is a very suitable platform for me." Jiang Hao said that he had exchanged with Academician Wei Yuquan of West China Hospital for many times, so he learned that the clinical resources of West China Hospital were very rich, so he always had the idea of going to West China Hospital.
In 2019, Jiang Hao was transferred to West China Hospital of Sichuan University, and in the same year, he was awarded the title of "Innovation Leader" in Sichuan Province, mainly engaged in the research of tumors, aging and aging-related diseases, while exploring new methods and new drugs for the diagnosis and treatment of anti-tumor and anti-aging from the perspective of protein phase change, and has published a number of relevant academic papers in internationally renowned journals such as Cell, Developmental Cell, Journal of Cell Biology.
Respond to tumor prevention and treatment with three major platforms
"All along, my original intention has not changed. So how can it have an impact on society? In Jiang Hao's view, coming to West China Hospital is an important step to realize his original intention, but this is obviously not enough, "How should my ideas, achievements, and technologies be exported and transformed?" Under such thinking, it did not take long for Sichuan Proheles Biotechnology Co., Ltd. to come into being.
The company was founded in 2021, Jiang Hao is the founder, the company currently has clinical trace samples big data multi-target diagnosis platform, phase transformation and drug platform and in vitro tumor drug screening platform three major platforms. "We are determined to develop early screening and early treatment of gastrointestinal tumors and to find new methods and mechanisms to delay aging." Jiang Hao said.
He believes that the current early screening of tumors is a difficult point in tumor prevention and treatment, especially after the discovery of digestive tract tumors due to the limitations of early screening technology, most of them are in the advanced stage, and the early screening molecular pathological diagnosis of the market is also mostly in single-target methylation and microRNA, and the diagnostic accuracy and sensitivity are in urgent need of breakthrough.
Based on this background, Jiang Hao's clinical trace sample big data multi-target diagnosis platform relies on ATAC-seq and Olink technology to conduct early screening diagnosis of different tumors with minimally invasive, trace, precise and multi-target, breaking through the drawbacks and blind spots of existing tumor early screening.
The use of protein phase transformation and the drug-ready platform can greatly improve the titer of protein target drugs and reduce the cost of clinical treatment of drugs, greatly changing the reality of expensive clinical applications of existing protein drugs.
The in vitro tumor drug screening platform uses the in vitro spindle system optimized by Jiang Hao's team to conduct large-scale screening of drugs that play a role in tumor division, and the above two platforms can provide drug transformation services and screening services for the pharmaceutical industry.
"At present, the company has a team of nearly 20 people, most of whom are researchers, and I am very optimistic about the prospects of this industry." Jiang Hao said.
(According to respondents)
<b>[If you have a news thread, please report to us, once adopted, there is a fee reward.] Newspaper WeChat attention: ihxdsb, newspaper QQ: 3386405712].</b>